Skip to main content
Premium Trial:

Request an Annual Quote

Canon Shareholders Say Firm Can Begin Making, Selling Microarrays

NEW YORK, March 30 (GenomeWeb News) - Canon may soon enter the microarray market.


Shareholders of the electronics giant today approved an amendment to the firm's articles of incorporation that will allow Canon to move forward with its plans to produce and commercialize its own line of microarrays.


The move represents a new step forward for the company, which has been racking up array-related IP in the US and toying with the idea of entering the market with budget microarrays produced with its Bubble Jet printing technology.


Still, Canon made similar public gestures towards entering the market in 2001 and 2003, and has yet to back up its talk with product.


Following the approval, Canon spokesperson Richard Berger told IDG News Service in Tokyo that the company has yet to decide when and how it will launch its new product. The same news service reported that Canon has been providing chips for a research project paid for by the Japanese government in colon cancer.


The participants of the annual shareholders' meeting in Tokyo have added a platform to the company's charter that now allows the "production and sale of pharmaceutical products," under which microarrays are covered as a legitimate part of the firm's business.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.